Nomura has maintained its neutral rating and 268p target price for UK lender Barclays saying that while the first-quarter results were slightly better than expectations, the second-quarter outlook is 'deteriorating'.Barclays said that while the first-quarter performance was "encouraging", "the continued challenging market conditions mean it is too early to establish the trend for the year". According to Nomura, "The share price is likely to respond to expectations of future trends, rather than those of Q1; market sentiment has weakened since the first quarter and considerable macro uncertainties remain". Jefferies has maintained its cautious stance on pharmaceuticals giant AstraZeneca after the group missed consensus revenue estimates by eight per cent in the first quarter."Whilst we had pointed out previously that consensus revenue estimates were too high, the CORE EPS guidance cut and management change announcements were a surprise."Jefferies has reiterated its hold rating and 2,841p target price on the stock today.Peel Hunt has reiterated its buy recommendation for coffee shop, restaurant and hotel owner Whitbread following the group's full-year results.The broker notes that following speculation on the potential de-merger of Costa (on the announcement of the coming resignation of the division's Managing Director John Derkach and his replacement with Finance Director Chris Rogers), "we expect no specific news today"."The move seemed to heighten the possibility that the demerger will eventually take place. The shares have accelerated on this sentiment but this theme is likely to become stale," said analyst Paul Hickman."Our raised target price of 2,030p [from 1,860p previously] assumes that the existing consolidation discount to peer value comes out sooner rather than later.BC